<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136310">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02079480</url>
  </required_header>
  <id_info>
    <org_study_id>IM142-003</org_study_id>
    <nct_id>NCT02079480</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, PK, and PD of CD40 in Healthy Subjects</brief_title>
  <acronym>CD40 FIH</acronym>
  <official_title>Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986090 (Anti-CD40 dAb) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK)
      and pharmacodynamics (PD) of BMS-986090 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Safety and tolerability measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests</measure>
    <time_frame>Up to Day 85 after single dose of BMS-986090</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE = Adverse event
ECG = Electrocardiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of BMS-986090 single dose subcutaneous (SC) and intravenous (IV)</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of single dose BMS-986090 SC and IV</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of single dose BMS-986090 SC and IV</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of single dose BMS-986090 SC and IV</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal serum half-life (T-HALF) of single dose BMS-986090 SC and IV</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of single dose BMS-986090 IV</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of single dose BMS-986090 SC</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at terminal phase (Vz) of single dose BMS-986090 IV</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during steady state (Vss) of single dose BMS-986090 IV</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at terminal phase (Vz/F) of single dose BMS-986090 SC</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute bioavailability (F) of single dose BMS-986090 SC</measure>
    <time_frame>19 timepoints up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of multiple dose BMS-986090 SC</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of multiple dose BMS-986090 SC</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal serum half-life (T-HALF) of multiple dose BMS-986090 SC</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in one dosing Interval [AUC(TAU)] of multiple dose BMS-986090 SC</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) of multiple dose BMS-986090 SC</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over a dosing interval (Css-avg) of multiple dose BMS-986090 SC</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Fluctuation (DF) of multiple dose BMS-986090 SC</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC accumulation index (AI_AUC); ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose of BMS-986090 SC (multiple dose)</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax accumulation index (AI_Cmax); ratio of Cmax at steady state to Cmax after the first dose of BMS-986090 SC (multiple dose)</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of multiple dose BMS-986090 SC</measure>
    <time_frame>29 timepoints up to Day 85 (Panel 9)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-KLH immunoglobulin G (IgG) and IgM antibody levels of single dose BMS-986090 SC</measure>
    <time_frame>Up to Day 29 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of BMS-986090 following single SC / IV infusion measured by frequency of subjects with positive anti-drug-antibody (ADA) assessment and frequency of subjects who develop positive ADA following a negative baseline</measure>
    <time_frame>Up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor occupancy (RO) of BMS-986090 following single SC or IV infusion</measure>
    <time_frame>Up to Day 85 (Panel 1-8)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>Panel 1: BMS-986090 (0.5 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 0.5 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg  solution single dose subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: BMS-986090 (3 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 3 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg  solution single dose subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3: BMS-986090 (10 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 10 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg  solution single dose subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 30 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
And Keyhole limpet hemocyanin (KLH) 1 mg solution single intramuscular dose once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 100 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg  solution single dose subcutaneously once
And KLH 1 mg solution single intramuscular dose once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 6: BMS-986090 (100 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 100 mg solution single dose intravenously once
OR
Placebo matching with BMS-986090 0 mg  solution single dose intravenously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 300 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg  solution single dose subcutaneously once
And KLH 1 mg solution single intramuscular dose once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 8: BMS-986090 (750 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 750 mg solution single dose intravenously once
OR
Placebo matching with BMS-986090 0 mg  solution single dose intravenously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 9: BMS-986090 (150 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 150 mg solution subcutaneously once weekly for 4 weeks
OR
Placebo matching with BMS-986090 0 mg  solution subcutaneously once weekly for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986090</intervention_name>
    <arm_group_label>Panel 1: BMS-986090 (0.5 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 2: BMS-986090 (3 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 3: BMS-986090 (10 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 6: BMS-986090 (100 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 8: BMS-986090 (750 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 9: BMS-986090 (150 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with BMS-986090</intervention_name>
    <arm_group_label>Panel 1: BMS-986090 (0.5 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 2: BMS-986090 (3 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 3: BMS-986090 (10 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 6: BMS-986090 (100 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 8: BMS-986090 (750 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 9: BMS-986090 (150 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keyhole limpet hemocyanin</intervention_name>
    <arm_group_label>Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <other_name>KLH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Healthy male and female (of not childbearing potential), ages 18-45 years, inclusive

          -  BMI 18 to 32 kg/m2, inclusive

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  History of thrombophilia, venous or  arterial thromboembolism (VTE or ATE), including
             history of myocardial infarction (MI), cerebrovascular accident (CVA), pulmonary
             embolism (PE), deep vein thrombosis (DVT)

          -  Known or suspected autoimmune disorder, including but not limited to rheumatoid
             arthritis, fibromyalgia, systemic lupus erythematosis, polymyalgia rheumatica, giant
             cell arteritis, Behcet's disease, dermatomyositis, multiple sclerosis, moderate to
             severe asthma, any autoimmune vasculitis, autoimmune hepatitis, or any other active
             autoimmune disease for which a subject requires medical follow-up or medical
             treatment

          -  Any history of known or suspected congenital or acquired immunodeficiency state or
             condition that would compromise the subject's immune status (e.g.  history of
             splenectomy)

          -  Presence of any factors that would predispose the subject to develop infection e.g.,
             rectal fissures, poor dentition, open skin lesions, and presence of preexisting skin
             conditions that increase risks for injection site complications e.g. Behcet's
             Disease, Psoriasis, pustular dermatoses
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keyhole-limpet hemocyanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
